Moderna (0QFD) Stock Overview

A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. More details

0QFD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 23.58% per year

Risk Analysis

Shares are highly illiquid

0QFD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Moderna, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Moderna
Historical stock prices
Current Share Price	US$42.71
52 Week High	US$50.06
52 Week Low	US$20.28
Beta	1.06
1 Month Change	-2.42%
3 Month Change	n/a
1 Year Change	86.53%
3 Year Change	-64.43%
5 Year Change	n/a
Change since IPO	-68.74%

Recent updates

Shareholder Returns

	0QFD	GB Biotechs	GB Market
7D	0%	-2.3%	-0.3%
1Y	86.5%	21.4%	18.3%

Return vs Industry: 0QFD exceeded the UK Biotechs industry which returned 21.6% over the past year.

Return vs Market: 0QFD exceeded the UK Market which returned 19.1% over the past year.

Price Volatility

Is 0QFD's price volatile compared to industry and market?
0QFD volatility
0QFD Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.2%
Market Average Movement	5.7%
10% most volatile stocks in GB Market	11.8%
10% least volatile stocks in GB Market	3.1%

Stable Share Price: 0QFD's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0QFD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	4,700	Stéphane Bancel	www.modernatx.com

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.

Moderna, Inc. Fundamentals Summary

How do Moderna's earnings and revenue compare to its market cap?
0QFD fundamental statistics
Market cap	€16.21b
Earnings (TTM)	-€2.74b
Revenue (TTM)	€1.91b

8.5x

P/S Ratio

-5.9x

P/E Ratio

Is 0QFD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QFD income statement (TTM)
Revenue	US$2.23b
Cost of Revenue	US$3.78b
Gross Profit	-US$1.55b
Other Expenses	US$1.64b
Earnings	-US$3.19b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-8.05
Gross Margin	-69.89%
Net Profit Margin	-143.55%
Debt/Equity Ratio	8.0%

How did 0QFD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/29 11:29
End of Day Share Price	2026/05/14 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moderna, Inc. is covered by 45 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	Argus Research Company
Eliana Merle	Barclays
Huidong Wang	Barclays

Moderna (0QFD) Stock Overview

Rewards

Risk Analysis

Moderna, Inc. Competitors

Genus

Oxford Biomedica

Scancell Holdings

BioNTech

Price History & Performance

Recent News & Updates

Insufficient new directors

Moderna, Inc. to Report Q1, 2026 Results on May 01, 2026

Moderna, Inc., Annual General Meeting, May 06, 2026

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement with Moderna

Moderna, Inc. Receives Refusal-To-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, Mrna-1010

Arbutus Biopharma Corporation Announces Court Ruling on Patent Infringement Dispute over Lipid Nanoparticle Vaccine Technology

Recent updates

Insufficient new directors

Moderna, Inc. to Report Q1, 2026 Results on May 01, 2026

Moderna, Inc., Annual General Meeting, May 06, 2026

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement with Moderna

Moderna, Inc. Receives Refusal-To-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, Mrna-1010

Arbutus Biopharma Corporation Announces Court Ruling on Patent Infringement Dispute over Lipid Nanoparticle Vaccine Technology

Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026

Moderna, Inc. to Report Q4, 2025 Results on Feb 13, 2026

Moderna, Inc. Lowers Earnings Guidance for Full Year 2025

Moderna, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Moderna, Inc.(NasdaqGS:MRNA) dropped from FTSE All-World Index (USD)

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Value Index

he START Center for Cancer Research Doses First U.S. Patient in Moderna's Phase 1 Clinical Trial of mRNA-4106, A Pan-Tumor Antigen Therapy Candidate, in Solid Tumors

Moderna, Inc. to Report Q1, 2025 Results on May 01, 2025

Genevant Sciences and Arbutus Biopharma Corporation Initiate International Patent Infringement Enforcement Actions Against Moderna

Moderna, Inc., Annual General Meeting, Apr 30, 2025

Moderna, Inc. Re-Iterates Earnings Guidance for the Full Year 2025

Moderna, Inc. to Report Q4, 2024 Results on Feb 14, 2025

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

Shareholder Returns

Price Volatility

About the Company

Moderna, Inc. Fundamentals Summary

Earnings & Revenue